Početna stranicaCLIFF • OTCMKTS
add
Cordlife Group Ltd
Preth. zaklj. cijena
0,070 $
Godišnji raspon
0,069 $ - 0,17 $
Tržišna kapitalizacija
47,08 mil. SGD
Prosječna količina
72,00
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
SGX
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (SGD) | pro 2025.info | Godišnja promjena |
|---|---|---|
Prihod | 9,46 mil. | 13,52 % |
Operativni troškovi | 10,41 mil. | 1,84 % |
Neto dohodak | −5,55 mil. | −11,80 % |
Neto profitabilnost | −58,72 | 1,51 % |
Zarada po dionici | — | — |
EBITDA | −4,29 mil. | 19,64 % |
Efektivna porezna stopa | −29,22 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (SGD) | pro 2025.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 51,77 mil. | −15,32 % |
Ukupna imovina | 201,76 mil. | −7,08 % |
Ukupne obveze | 97,28 mil. | −1,42 % |
Ukupni kapital | 104,48 mil. | — |
Dionice u optjecaju | 256,31 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 0,17 | — |
Povrat imovine | −6,12 % | — |
Povrat kapitala | −11,53 % | — |
Tok novca
Neto promjena novca
| (SGD) | pro 2025.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −5,55 mil. | −11,80 % |
Gotovina od poslovanja | −751,00 tis. | −1.606,82 % |
Gotovina iz ulaganja | −6,59 mil. | 50,34 % |
Gotovina iz financiranja | −557,00 tis. | −106,95 % |
Neto promjena novca | −8,36 mil. | −45,26 % |
Slobodan tok novca | −894,00 tis. | — |
Više
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Glavni izvršni direktor
Osnovano
2. svi 2001.
Web-lokacija
Zaposlenici
111
